SUMMARY
The pathogenesis of heart failure with a preserved ejection fraction (HFpEF) is unclear. Myocardial fibrosis, inflammation, and cardiac hypertrophy have been suggested to contribute to the pathogenesis of HFpEF.
Cardiosphere-derived cells (CDCs) are heart-derived cell products with antifibrotic and anti-inflammatory properties. This study tested whether rat CDCs were sufficient to decrease manifestations of HFpEF in hypertensive rats. Starting at 7 weeks of age, Dahl salt-sensitive rats were fed a high-salt diet for 6 to 7 weeks and randomized to receive intracoronary CDCs or placebo. Dahl rats fed normal chow served as controls.
High-salt rats developed hypertension, left ventricular (LV) hypertrophy, and diastolic dysfunction, without impairment of ejection fraction. Four weeks after treatment, diastolic dysfunction resolved in CDC-treated rats but not in placebo. The improved LV relaxation was associated with lower LV end-diastolic pressure, decreased lung congestion, and enhanced survival in CDC-treated rats. Histology and echocardiography revealed no decrease in cardiac hypertrophy after CDC treatment, consistent with the finding of sustained, equally-elevated blood pressure in CDC-and placebo-treated rats. Nevertheless, CDC treatment decreased LV fibrosis and inflammatory infiltrates. Serum inflammatory cytokines were likewise decreased after CDC treatment. Whole-transcriptome analysis revealed that CDCs reversed changes in numerous transcripts associated with HFpEF, including many involved in inflammation and/or fibrosis. These studies suggest that CDCs normalized LV relaxation and LV diastolic pressure while improving survival in a rat model of HFpEF. H eart failure with preserved ejection fraction (HFpEF) has become a major public health concern. Its increasing prevalence now exceeds that of heart failure with reduced ejection fraction (1) (2) (3) . Outcomes of patients with HFpEF are poor (4, 5) , and so far, no treatment has been shown to decrease morbidity or mortality (3, 6) . HFpEF is associated with various cardiovascular risk factors (especially hypertension), extracardiac comorbidities, and aging. The net result is impaired diastolic relaxation and filling of the left ventricle, increased myocardial stiffness, impaired vascular compliance, and increased diastolic pressure (7, 8) . Myocardial fibrosis and inflammation have been associated with HFpEF (9-14) and with the transition from hypertensive left ventricular (LV) hypertrophy without HFpEF to hypertensive LV hypertrophy with HFpEF (15).
Cardiosphere-derived cells (CDCs) are heart cell products with antifibrotic, anti-inflammatory, and angiogenic properties (16) (17) (18) (19) (20) . CDCs, which are currently in phase 2 human trials for scar reduction after myocardial infarction (5) , have been shown to be beneficial in models of ischemic (17, 18, 21) and nonischemic cardiomyopathy (16) . Thus, we wondered whether CDCs might have disease-modifying activity in HFpEF.
Dahl salt-sensitive (DS) rats develop hypertension, hypertrophy, and, eventually, HFpEF on a high-salt diet (22) (23) (24) (25) (26) . Increased fibrosis and inflammation underlie the development of HFpEF, with resultant cachexia, pulmonary congestion, and accelerated mortality (22, 26, 27) . Therefore, this model has been widely used to test new treatments for HFpEF (23, (27) (28) (29) (30) (31) . Here, we tested the efficacy of CDCs in improving LV structure and function and overall outcome in DS rats with HFpEF.
METHODS
An expanded "Methods" section is available in the Supplemental Appendix.
DS rats (Charles River, Wilmington, Massachusetts) were fed a 0.3% NaCl (low-salt) diet until 7 weeks of age. At that time, the diet was switched to an 8% NaCl (high-salt) diet in 54 rats by random assignment. DS rats fed the low-salt diet constituted the control group (n ¼ 18). At 13 to 14 weeks of age, rats on the high-salt diet were randomized to grown from a freshly explanted Wistar-Kyoto rat heart as previously described (19) ( Figure 1B) .
Echocardiography was performed at baseline, before treatment, and 1 and 4 weeks after treatment to assess systolic and diastolic function. Invasive hemodynamic measurements were performed at endpoint to record systemic pressure and LV pressures and volumes. Pressure-volume loops were generated from these recordings. Rats were then euthanized and hearts were harvested for analysis.
Additional follow-up (7 rats in each group, randomly chosen from the rats alive at 4 weeks) placebo-and CDC-treated rats; 1 week post-treatment, n ¼ 10 for control rats, n ¼ 21 for placebo-and CDC-treated rats; at endpoint, n ¼ 10 for control rats, n ¼ 15 for placebo-treated rats, n ¼ 18 for CDC-treated rats). Figure 1C shows representative images of transmitral flow at endpoint in control, placebo-treated, and CDC-treated animals. Pooled data ( Figure 1D ) revealed that after 6 weeks of diet but before treatment, E/A ratios were similar in the placebo and CDC groups but lower than in control rats.
Likewise, left atrial size was higher in the high-salt-fed rats compared with control rats, indicating already increased LV filling pressure. After intracoronary infusion of CDCs (but not placebo), E/A ratio increased over time ( Figure 1D ), a change that was evident as soon as 1 week after treatment. At endpoint, E/A ratios had returned to control levels in CDC-treated animals (1.7 AE 0.2 for CDC-treated vs. 1.8 AE 0.16 for control rats, p ¼ 0.36), whereas they remained depressed in placebo-treated animals would have been associated with increased LVEDP and tau [32] ).
We did not observe any differences in blood pressure or heart rate between CDC-and placebo-treated animals that could have confounded relaxation and LVEDP measurements (although blood pressure was lower in the control group, as expected) ( Figures 2H   to 2J) . Thus, the improvements in diastolic function were not due to antihypertensive or chronotropic effects of CDCs. The differences between CDC-and placebo-treated rats are not related to changes in systolic blood pressure (SBP) (H) or diastolic blood pressure (DBP) (I) or heart rate (HR) (J) (n ¼ 8 for control rats and n ¼ 12 for placebo-and CDC-treated rats; for PV loop families, n ¼ 6 for control rats, n ¼ 7 for placebo-treated rats, and n ¼ 8 for CDC-treated rats). *p < 0.05 versus placebo-and CDC-treated rats, †p < 0.05 versus control and CDC-treated rats, and ‡p < 0.05, all by analysis of variance.
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p ¼ 0.027). Post-mortem lung weight and lung weight/body weight ratios were higher in placebo-treated rats, indicative of pulmonary congestion ( Figure 3B ). In parallel, Figure 3C shows that animals treated with CDCs resumed some physiological weight gain, while placebo rats lost weight, presumably because of cardiac cachexia (an impression that was confirmed visually).
MECHANISM. Improvement of LV relaxation is not associated with quantitative changes in cardiac hypertrophy. LV hypertrophy (both macroscopic and cellular) can occur with or without diastolic dysfunction. We quantified cardiac hypertrophy using LV wall thickness by echocardiography, heart weight, and cardiomyocyte cross-sectional area.
Notably, the CDC-related improvement in diastolic function was not due to a decrease in cardiac hyper- Cardiac anterior wall (AW) and posterior wall (PW) thickness by echocardiography (A), heart weight and heart weight/body weight ratio (B), and cross-sectional cardiomyocyte area (CSA) (C) are equally elevated in placebo-and cardiosphere-derived cell (CDC)-treated rats relative to control. n ¼ 10 for control rats, n ¼ 15 for placebo-treated rats, and n ¼ 18 for CDC-treated rats in A; n ¼ 6, n ¼ 11, and n ¼ 14, respectively, in B; n ¼ 5 in each group in C. *p < 0.05 versus placebo-and CDC-treated rats by analysis of variance.
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Cell Therapy With CDCs in HFpEF a-smooth muscle actin (SMA) in control and placebo-and CDC-treated rats. Myofibroblast infiltration into the heart is higher in placebo-than in CDC-treated and control rats. n ¼ 6 to 8 in each group. †p < 0.05 versus control and CDC-treated rats by analysis of variance.
Ki67 immunostaining ( Figure 7D ) revealed that CDCs stimulated cardiomyocyte proliferation (cells positive for both a-sarcomeric actinin and Ki67) ( Figure 7E ).
In contrast, the number of proliferating fibroblasts (Ki67-positive, vimentin-positive cells) was greatly increased in placebo-treated (but not CDC-treated)
high-salt DS rat hearts relative to low-salt control rats ( Figure 7F) .
N e x t -g e n e r a t i o n r i b o n u c l e i c a c i d s e q u e n c i n g .
Next-generation sequencing was performed in the Gallet et al.
Cell Therapy With CDCs in HFpEF Figure 8B ). Indeed, key genes involved in fibrosis, inflammation, and macrophage signaling, or associated with the consequences of HFpEF (brain natriuretic and atrial natriuretic peptides), were upregulated in placebo hearts but returned fully or partially to control levels after CDC treatment.
These profound changes in the transcriptome reveal
HFpEF-related activation, and CDC-induced inhibition, of key disease-associated signaling and effector pathways ( Figure 8C ).
DISCUSSION
The challenge of HFpEF is increasing as the population ages and comorbidities become more Gallet et al.
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